238 related articles for article (PubMed ID: 29588516)
1. Market watch: Top drugs and companies by sales in 2017.
Urquhart L
Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
[No Abstract] [Full Text] [Related]
2. Making the move into drug sales.
Willerroider M
Nature; 2004 Jul; 430(6998):486-7. PubMed ID: 15269778
[No Abstract] [Full Text] [Related]
3. Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.
Polanski J; Bogocz J; Tkocz A
Drug Discov Today; 2015 Nov; 20(11):1300-4. PubMed ID: 26160060
[TBL] [Abstract][Full Text] [Related]
4. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
Lexchin J
Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
[TBL] [Abstract][Full Text] [Related]
5. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
6. Market watch: Specialty pharmaceuticals to provide majority of sales by 2012.
Goodman M
Nat Rev Drug Discov; 2009 Mar; 8(3):184. PubMed ID: 19247297
[No Abstract] [Full Text] [Related]
7. Regulation of clinical research sponsored by pharmaceutical companies: a proposal.
Sotelo J
PLoS Med; 2006 Jul; 3(7):e306. PubMed ID: 16805651
[TBL] [Abstract][Full Text] [Related]
8. Research and development costs for drugs.
Riggs TL
Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
[No Abstract] [Full Text] [Related]
9. US drug sales continue to rise.
Gottlieb S
BMJ; 2003 Mar; 326(7388):518. PubMed ID: 12623895
[No Abstract] [Full Text] [Related]
10. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
11. Pharmaceuticals and medical devices: business practices. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
[No Abstract] [Full Text] [Related]
12. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
Buckely M
Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
[No Abstract] [Full Text] [Related]
13. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
Giri I; Rouillon F
Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
[No Abstract] [Full Text] [Related]
14. Market watch: upcoming market catalysts in Q3 2012.
Jeng R
Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
[No Abstract] [Full Text] [Related]
15. Issues in bringing new drugs to the market.
Ammann AJ
Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329171
[No Abstract] [Full Text] [Related]
16. Priced out of the UK market.
Moran N
Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
[No Abstract] [Full Text] [Related]
17. FDA chief attacks Canada's drug price controls.
Webster P
Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
[No Abstract] [Full Text] [Related]
18. Patent indicators: a window to pharmaceutical market success.
Guo Y; Hu Y; Zheng M; Wang Y
Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
20. Illegitimate companies threaten patients' receipt of FDA-approved drugs.
Thompson CA
Am J Health Syst Pharm; 2013 Oct; 70(19):1646-7. PubMed ID: 24048594
[No Abstract] [Full Text] [Related]
[Next] [New Search]
